1. Home
  2. REGN vs TEL Comparison

REGN vs TEL Comparison

Compare REGN & TEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • TEL
  • Stock Information
  • Founded
  • REGN 1988
  • TEL 1941
  • Country
  • REGN United States
  • TEL Ireland
  • Employees
  • REGN N/A
  • TEL N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • TEL Industrial Machinery/Components
  • Sector
  • REGN Health Care
  • TEL Technology
  • Exchange
  • REGN Nasdaq
  • TEL Nasdaq
  • Market Cap
  • REGN 59.5B
  • TEL 61.0B
  • IPO Year
  • REGN 1991
  • TEL 2007
  • Fundamental
  • Price
  • REGN $568.20
  • TEL $212.42
  • Analyst Decision
  • REGN Buy
  • TEL Buy
  • Analyst Count
  • REGN 23
  • TEL 10
  • Target Price
  • REGN $794.83
  • TEL $196.50
  • AVG Volume (30 Days)
  • REGN 991.3K
  • TEL 1.6M
  • Earning Date
  • REGN 10-30-2025
  • TEL 10-29-2025
  • Dividend Yield
  • REGN 0.62%
  • TEL 1.34%
  • EPS Growth
  • REGN 5.03
  • TEL N/A
  • EPS
  • REGN 39.67
  • TEL 4.83
  • Revenue
  • REGN $14,214,200,000.00
  • TEL $16,581,000,000.00
  • Revenue This Year
  • REGN N/A
  • TEL $8.90
  • Revenue Next Year
  • REGN $4.97
  • TEL $8.47
  • P/E Ratio
  • REGN $14.32
  • TEL $43.95
  • Revenue Growth
  • REGN 5.38
  • TEL 4.86
  • 52 Week Low
  • REGN $476.49
  • TEL $116.30
  • 52 Week High
  • REGN $1,170.58
  • TEL $215.22
  • Technical
  • Relative Strength Index (RSI)
  • REGN 50.07
  • TEL 68.97
  • Support Level
  • REGN $552.98
  • TEL $206.27
  • Resistance Level
  • REGN $588.70
  • TEL $209.92
  • Average True Range (ATR)
  • REGN 16.19
  • TEL 3.20
  • MACD
  • REGN -3.04
  • TEL -0.15
  • Stochastic Oscillator
  • REGN 26.70
  • TEL 80.91

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About TEL TE Connectivity Ltd. New Switzerland Registered Shares

TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.

Share on Social Networks: